SAN DIEGO, May 3, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, today announced it will release financial results for the first quarter ended March 31, 2013, after the market closes on Thursday, May 9, 2013, and will hold a conference call on this day at 4:30 p.m. ET (1:30 p.m. PT), to discuss these financial results and provide a company update. To access the live webcast please visit the Company's Investor Relations website at ir.zogenix.com, and to participate, please dial (866) 318-8616 (U.S.) or (617) 399-5135 (International); participant passcode: 65838569. The conference call will be hosted by Chief Executive Officer Roger L. Hawley, President Stephen J. Farr, Ph.D., and Executive Vice President and Chief Financial Officer Ann Rhoads. A replay of the conference call will be available beginning May 9, 2013 at 6:30 p.m. ET (3:30 p.m. PT) until May 16, 2013, by dialing (888) 286-8010 (U.S.) or (617) 801-6888 (International); passcode: 23471504. A replay of the webcast will also be accessible on the Investor Relations website for one month, through June 9, 2013. About Zogenix Zogenix, Inc. (Nasdaq:ZGNX), with offices in San Diego and Emeryville, California, is a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain. Zogenix's first commercial product, SUMAVEL® DosePro® (sumatriptan injection) Needle-free Delivery System, was launched in January 2010 for the acute treatment of migraine and cluster headache. Zogenix's lead investigational product candidate, Zohydro™ ER (hydrocodone bitartrate), is an oral, extended-release formulation of various strengths of hydrocodone, without acetaminophen, intended for administration every 12 hours for around the clock management of moderate to severe chronic pain. In May 2012, Zogenix submitted to the FDA a New Drug Application for Zohydro ER. Zogenix's second investigational product candidate, Relday™, is a proprietary, long-acting injectable formulation of risperidone for the treatment of schizophrenia; an investigational new drug application was submitted to the FDA in May 2012. For additional information, please visit www.zogenix.com .
CONTACT: INVESTORS: Zack Kubow | The Ruth Group 646.536.7020 | firstname.lastname@example.org MEDIA: Caitlin Cox | The Ruth Group 646.536.7033 | email@example.com